GlassScriptPhysician profile
Ricardo Salas
NPI 1497045355
$12,984.97
in general payments reported to CMS, 2019-2025
43 companies · $311 in 2025
The $311 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $938 · 2020: $789 · 2021: $703 · 2022: $453 · 2023: $9,280 · 2024: $510 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,830 · Food and Beverage: $1,243 · Education: $28.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,830.00 |
| Food and Beverage | $1,242.77 |
| Education | $28.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $8,830.00 | 2023 | Yescarta |
| E.R. Squibb & Sons, L.L.C. | $680.09 | 2019-2024 | Opdivo |
| Pfizer INC. | $372.82 | 2019-2025 | |
| Amgen INC. | $350.80 | 2019-2023 | Nplate, Vectibix, Xgeva |
| Daiichi Sankyo INC. | $320.81 | 2020-2024 | Injectafer, Vanflyta |
| Janssen Biotech, INC. | $265.47 | 2020-2025 | Talvey, Darzalex, Tecvayli |
| Genentech USA, INC. | $198.22 | 2019-2023 | Phesgo |
| Astrazeneca Pharmaceuticals LP | $194.24 | 2020-2025 | Tagrisso, Imfinzi, Enhertu |
| Lilly USA, LLC | $174.72 | 2019-2024 | Verzenio |
| Eisai INC. | $167.29 | 2020-2023 | |
| Exelixis INC. | $158.00 | 2019-2023 | Cabometyx |
| Astellas Pharma US INC | $150.27 | 2023-2025 | Vyloy, Xospata, Padcev |
| Merck Sharp & Dohme LLC | $133.80 | 2019-2025 | Keytruda, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $116.80 | 2019-2025 | |
| Incyte Corporation | $80.86 | 2019-2025 | Jakafi, Monjuvi |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricardo Salas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.